Across Britain, Europe and the US, a common but often ignored night-time condition is quietly chewing through public finances and company profits.
Obstructive sleep apnoea, long seen as a niche sleep disorder, is now emerging as a major economic threat, driving absenteeism, mistakes at work and soaring healthcare costs throughout high‑income countries.
The hidden night-time disorder costing tens of billions
Obstructive sleep apnoea (OSA) happens when the upper airway repeatedly collapses during sleep. Breathing stops or becomes very shallow for several seconds at a time. The brain responds by jolting the sleeper awake, often so briefly they do not remember it.
These micro-awakenings can occur dozens of times an hour. The result is a night of broken, low‑quality sleep that leaves people exhausted, irritable and struggling to focus the next day.
Classic signs include loud, chronic snoring, gasping or choking during the night and a powerful tendency to fall asleep during the day – at work, on the sofa, or at the wheel. Over years, OSA raises the risk of heart attacks, strokes, high blood pressure and type 2 diabetes.
Researchers now estimate that obstructive sleep apnoea is costing the US and UK alone around €137 billion a year in lost productivity.
That figure comes from an analysis led by University College London using data from more than 4,000 adults in the UK and US. The team looked at sick leave, reduced performance while at work and other indicators of productivity loss.
The 137‑billion‑euro bill only covers the hit to economic output. It does not include extra medical spending or the cost of road and workplace accidents linked to fatigue, meaning the true burden is likely far higher.
An epidemic largely going undiagnosed
OSA is not a rare condition lurking in the margins of the health system. European data suggest roughly 18% of adults show signs compatible with obstructive sleep apnoea – close to one in five people.
Yet most of those affected have no formal diagnosis. Studies indicate that up to 85% of cases remain unidentified. Many people blame their tiredness on stress, long hours or age. Partners may complain about snoring, but few see it as a medical issue with economic consequences.
➡️ Unexpected find: thousands of fish nests spotted beneath Antarctic ice
➡️ Every autumn, gardeners make the same mistake with their leaves
➡️ This warm baked recipe feels dependable in the best way
➡️ This plant that can stop mold is becoming the ideal natural solution for bathrooms and damp rooms
In wealthy European countries, OSA has been estimated to cost around €184 billion per year, making it the most expensive sleep disorder on the continent.
The heaviest share of that cost does not come from hospital bills or sleep clinics. It stems from what economists call “indirect costs” – work missed due to illness and, even more significantly, workers who show up but are simply not functioning at full capacity.
Presenteeism: present at work, but not really there
Presenteeism describes being at work while sick, exhausted or in pain and, as a result, performing well below one’s usual potential. For OSA, this has become a key economic issue.
- People with untreated OSA often struggle with concentration and memory.
- They make more mistakes and work more slowly.
- They are more likely to be involved in workplace accidents, especially in safety‑critical jobs.
When scaled across millions of workers, even a modest drop in performance translates into staggering financial losses. For employers, those costs are often invisible on balance sheets but very real in daily operations.
A blind spot in public health strategies
Despite its reach, OSA still sits in the shadows of national health planning. Public messaging around sleep tends to focus on screen time and good habits, while sleep apnoea screening remains patchy and reactive, often initiated only after years of symptoms.
The standard treatment is continuous positive airway pressure (CPAP). Patients wear a small mask at night connected to a machine that blows air into the throat to keep the airway open. When used regularly, CPAP can transform lives: snoring stops, sleep deepens, and daytime alertness returns.
Yet many people abandon CPAP within months. Complaints range from mask discomfort and noise to the psychological burden of needing a machine to sleep. Others never make it that far because they never reach a specialist clinic in the first place.
Economists argue that earlier diagnosis and better support for treatment adherence could pay for themselves many times over through higher productivity and lower cardiovascular risk.
Treatment options beyond the sleep lab
For those who cannot tolerate CPAP, other options exist. Dentists can fit mandibular advancement devices — mouthpieces that push the lower jaw slightly forward to keep the airway open. These are often effective in mild to moderate cases.
Weight loss is another pillar, since excess tissue around the neck increases pressure on the airway during sleep. Even a modest reduction in body weight can significantly lower OSA severity for some people. In specific situations, positional therapy, surgery or newer nerve‑stimulating implants may be considered.
Yet access to these options varies widely by country, insurance coverage and income level. Many patients simply live with the symptoms, assuming constant fatigue is normal.
Why companies are starting to pay attention
As the economic data grow harder to ignore, some large employers and insurers are testing targeted programmes for sleep health. The logic is straightforward: a relatively cheap home sleep test and basic treatment may prevent costly mistakes, burnout and health claims later on.
Industries where alertness is critical – aviation, road transport, heavy industry, healthcare – face particular pressure. An undiagnosed OSA sufferer in a lorry cab or at an operating table is not just a productivity problem but a safety risk.
| Impact area | How OSA contributes | Economic consequence |
|---|---|---|
| Work performance | Impaired focus, slower decision-making | Lower output per worker |
| Absenteeism | More sick days due to fatigue and related illness | Lost working days, disruption of teams |
| Accidents | Microsleeps, reduced reaction time | Insurance claims, legal costs, reputational damage |
| Healthcare use | Higher rates of heart disease, hypertension, stroke | Increased medical spending over decades |
What obstructive sleep apnoea actually feels like
For those who have never experienced it, the condition can sound abstract. The day‑to‑day reality is often brutal. People wake with headaches, a dry mouth and a sense of having barely slept. They may nod off in meetings or while reading, and some admit to fighting sleep at traffic lights.
Partners report grinding snoring, long pauses in breathing followed by gasps and sudden jerks. In some households, couples sleep in separate rooms just to get through the night, adding strain to relationships that rarely shows up in economic spreadsheets.
Simple questions that can flag a hidden problem
Doctors often use quick screening tools before sending someone for a sleep study. Without offering diagnosis, a few red flags can signal that a conversation is overdue:
- Do you snore loudly, most nights?
- Has anyone seen you stop breathing or gasp during sleep?
- Do you feel extremely sleepy or foggy during the day?
- Do you wake with morning headaches or choking sensations?
- Do you have high blood pressure, especially if difficult to control?
A “yes” to several of these does not prove OSA, but it strongly suggests that fatigue is not just about late nights and stress.
Looking ahead: small changes, big macro impact
Health economists who model future costs note that Western populations are ageing and obesity rates remain high. Both trends favour a further rise in OSA cases. Left unchecked, that means more pressure on health budgets and weaker productivity growth in economies already worried about stagnation.
On the other hand, targeted interventions are relatively straightforward. Training GPs to ask the right questions, funding more home sleep tests, and supporting long‑term adherence to therapy could shift the curve. Even a modest reduction in the severity of symptoms across millions of workers might free up billions currently lost to tired minds and drowsy commutes.
For individuals, recognising that constant exhaustion is not a personal failing but a potentially treatable medical problem can be a turning point. For governments and employers, treating sleep as core infrastructure for a healthy economy may turn out to be less radical than it sounds — and far cheaper than ignoring what happens after lights out.